NIT is focused on the identification of biomarkers in cancer progression, angiogenesis and metastasis, and characterization of glycan-based recognition of molecular cues in oncogenesis.This fundamental knowledge assists the development of novel biosensors for diagnostics and on the design of better and innovative therapies to fight cancer.
NIT outstanding contributions to elucidate exosome trafficking, modulation of the tumor microenvironment and angiogenesis and the role of glycans in cancer progression, metastasis and evasion of immune response, has paved the way to optimize novel immunotherapies (antibodies and dendritic cells; proprietary technology) and novel targeted nanomedicines against cancer (particularly colorectal, breast and lung carcinomas). Several molecular marks have been targeted:
i) gene silencing and controlling crucial genes;
ii) targeted drug delivery;
iii) controlling exosomes malignant transformation of normal cells;
iv) localized hyperthermia against cancer.
NIT is strongly committed to develop molecular biosensors towards portable devices for diagnostics. This work has allowed to integrate multidisciplinary international networks (MSCAITN-GlycoCan; ERA-Net; and M-ERA-Net) in prolific collaborations with biopharma.